These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18923671)

  • 21. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.
    Belser JA; Szretter KJ; Katz JM; Tumpey TM
    Virology; 2013 Apr; 439(1):42-6. PubMed ID: 23453580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.
    Rameix-Welti MA; Agou F; Buchy P; Mardy S; Aubin JT; Véron M; van der Werf S; Naffakh N
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3809-15. PubMed ID: 16940075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza virus susceptibility and resistance to oseltamivir.
    Aoki FY; Boivin G; Roberts N
    Antivir Ther; 2007; 12(4 Pt B):603-16. PubMed ID: 17944268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
    Abed Y; Baz M; Boivin G
    J Infect Dis; 2009 Jan; 199(2):180-3. PubMed ID: 19046066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral management of seasonal and pandemic influenza.
    Hayden FG; Pavia AT
    J Infect Dis; 2006 Nov; 194 Suppl 2():S119-26. PubMed ID: 17163384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
    Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
    Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.
    Muñoz FM; Anderson EJ; Deville JG; Clinch B; Kamal MA
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):531-40. PubMed ID: 26042486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oseltamivir resistance in influenza A (H5N1) infection.
    Gupta RK; Nguyen-Van-Tam JS
    N Engl J Med; 2006 Mar; 354(13):1423-4; author reply 1423-4. PubMed ID: 16571890
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.
    Karsch K; Chen X; Miera O; Peters B; Obermeier P; Francis RC; Amann V; Duwe S; Fraaij P; Heider A; de Zwart M; Berger F; Osterhaus A; Schweiger B; Rath B
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):155-164. PubMed ID: 26994602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients.
    Ison MG; Szakaly P; Shapira MY; Kriván G; Nist A; Dutkowski R
    Antivir Ther; 2012; 17(6):955-64. PubMed ID: 22728756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.
    Hung IFN; To KKW; Chan JFW; Cheng VCC; Liu KSH; Tam A; Chan TC; Zhang AJ; Li P; Wong TL; Zhang R; Cheung MKS; Leung W; Lau JYN; Fok M; Chen H; Chan KH; Yuen KY
    Chest; 2017 May; 151(5):1069-1080. PubMed ID: 27884765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.
    Lemaitre F; Luyt CE; Roullet-Renoleau F; Nieszkowska A; Zahr N; Corvol E; Fernandez C; Antignac M; Farinotti R; Combes A
    Ther Drug Monit; 2012 Apr; 34(2):171-5. PubMed ID: 22354159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.
    Rath B; von Kleist M; Tief F; Karsch K; Tuerk E; Muehlhans S; Louis F; Skopnik H; Schweiger B; Duwe S
    Pediatr Infect Dis J; 2012 Sep; 31(9):899-905. PubMed ID: 22581220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation.
    Kawai N; Ikematsu H; Iwaki N; Kondou K; Hirotsu N; Kawashima T; Maeda T; Tanaka O; Doniwa K; Kashiwagi S
    J Infect; 2009 Sep; 59(3):207-12. PubMed ID: 19619898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The course of fever following influenza virus infection in children treated with oseltamivir.
    Suzuki E; Ichihara K
    J Med Virol; 2008 Jun; 80(6):1065-71. PubMed ID: 18428131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic characterization of circulating seasonal Influenza A viruses (2005-2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India.
    Agrawal AS; Sarkar M; Ghosh S; Roy T; Chakrabarti S; Lal R; Mishra AC; Chadha MS; Chawla-Sarkar M
    Infect Genet Evol; 2010 Dec; 10(8):1188-98. PubMed ID: 20678590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed oseltamivir treatment is associated with longer viral shedding of pandemic (H1N1) 2009 virus.
    Leung YH; Lim WL; Wong MH; Chuang SK
    Epidemiol Infect; 2012 May; 140(5):814-7. PubMed ID: 21801465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of oseltamivir-resistant influenza A/H3N2 virus with altered hemagglutination pattern in a hematopoietic stem cell transplant recipient.
    Cohen-Daniel L; Zakay-Rones Z; Resnick IB; Shapira MY; Dorozhko M; Mador N; Greenbaum E; Wolf DG
    J Clin Virol; 2009 Feb; 44(2):138-40. PubMed ID: 19157971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
    Tarkiainen EK; Backman JT; Neuvonen M; Neuvonen PJ; Schwab M; Niemi M
    Clin Pharmacol Ther; 2012 Jul; 92(1):68-71. PubMed ID: 22588607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.